Independent Conference Highlights of the 2022 ASH Annual Meeting*

Download All
December 10-13, 2022; New Orleans, Louisiana
Expert faculty review and share their insights and perspectives on key findings in lymphomas presented at the 2022 ASH Annual Meeting.

Lymphomas

Slidesets TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL
Slidesets Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL
Slidesets Pooled Analysis of PhaseED-Seq MRD-Negativity Assessment as Surrogate Endpoint After Frontline Induction Therapy in Patients With DLBCL
Slidesets Phase II Trial: Updated Results of Frontline Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Untreated High-Risk CLL
Slidesets Phase I/II EPCORE NHL-2 Trial Update: Epcoritamab + Rituximab/Lenalidomide in Follicular Lymphoma
Slidesets Acalabrutinib + Lenalidomide and Rituximab With MRD Monitoring in Previously Untreated Mantle Cell Lymphoma
Slidesets Extended Follow-up Results From a Pilot Study of Brentuximab Vedotin + AVD in Newly Diagnosed, Early-Stage, Unfavorable-Risk cHL Using Baseline MTV and PET2 Evaluation
Slidesets CAPTIVATE: 5-Yr Follow-up of Continued Ibrutinib vs Placebo in Patients With CLL/SLL and Undetectable MRD After First-line Ibrutinib + Venetoclax
Slidesets SYMPHONY-1: Phase Ib Results of Tazemetostat + Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Slidesets MATRix/IELSG43: Phase III Trial of High-Dose Chemotherapy + ASCT vs Nonmyeloablative Chemoimmunotherapy as Consolidation for Primary CNS Lymphoma
Slidesets ALPINE: Final Analysis of Zanubrutinib vs Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Amgen
Epizyme
GSK
Incyte Corporation
Jazz Pharmaceuticals
Karyopharm Therapeutics Inc.
Novartis Pharmaceuticals Corporation
Sanofi
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings